QS Research · Michael Burry's Scion Capital analyst template · 2006
TENET HEALTHCARE CORP (THC)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $291.54 (close 2026-11-16); latest close $263.19 (2026-11-20), -9.7% since the report; figures re-marked at the latest close
Conclusion: WATCH
Conviction low · base case +46% · downside -17% · upside +77%
THC is priced at 1.52x TTM EV/Sales, with the market treating the Q3 2026 Conifer transition benefit and the 2027 reimbursement and payer-mix warnings as permanent even though FY2026 guidance is $5.05-$5.20B Adjusted EBITDA and TTM free cash flow is $3.33B. The call is WATCH because the evidence cuts both ways: ROIC of 23.8% against a 7.0% WACC passes the quality test, but there is no durable moat and the headline run rate is inflated. The downside case is $218.11, -25.2%, on -1.5% sales at a compressed EV/Sales of 1.29x (today 1.52x). The base case is $383.67, +31.6%, on EV/Sales at 1.85x, the peer median EV/Sales. The upside case is $465.30, +59.6%, on a re-rating to 1.99x on the cited dated catalyst.
Key numbers
- Share price: $263.19
- Market cap: $20.95B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $22.15B
- EV / EBITDA (TTM): 5.0x
- P/E (TTM): 7.2x
- FCF yield: 15.8%
- Price / book: 3.85x
- Earnings-quality flags (TTM): none flagged
- P/E, operating (tax-normalized) (TTM): 6.0x
- EV / FCF (TTM): 9.4x
- Revenue growth (latest fiscal year): +3.1%
- ROIC (TTM): 23.8%
- WACC: 6.9%
- Economic profit spread: +17.0 pts
The 15 boxes
- ✓ 1. Long-form business notes
Tenet makes money through two FY2025 segments: Hospital Operations (50 acute care and specialty hospitals, 132 outpatient facilities, plus Conifer revenue-cycle management) and Ambulatory Care (USPI interests in 533 ASCs and 26 surgical hospitals at Dec. 31, 2025). Since the FY2020 report, the company went from three segments including a planned Conifer spin-off to two segments and full Conifer ownership in January 2026, while cutting hospitals from 65 to 50 and licensed beds from 17,178 to 12,494. FY2025 revenue was $21.31B with $3.51B operating income and $1.41B net income to common; TTM to Sep. 2026 revenue was $22.15B with $5.40B operating income and $2.90B net income to common. Cash generation is large: $3.54B FY2025 operating cash flow and $4.24B TTM, with $1.39B FY2025 and $1.81B TTM buybacks reducing diluted shares to 83.08M TTM from 106.26M in FY2020.
- ✓ 2. Competitive advantage
The filings describe no durable moat: THC competes market-by-market on quality, location, service breadth, reputation and physician relationships, and its physicians can move patients to rivals at any time. It states a structural disadvantage versus not-for-profit and government-owned facilities (endowments, tax-exempt financing, tax exemptions, discounted drug pricing) and heavy payer concentration — 70%, or $9.696 billion, of FY2025 Hospital Operations net patient service revenues came from managed care payers. What it does have is scale and cash generation: revenue $21.31B in FY2025 and $22.15B TTM to 2026-09-30, operating income $3.51B and $5.40B, operating cash flow $3.54B and $4.24B, funding $1.39B and $1.81B of buybacks. That is a scale-and-cash story in a price-competitive, low-switching-cost business, not a franchise.
- ✓ 3. 10-Q takeaways
Q3 2026 (quarter ended 2026-09-30) shows 6.5% revenue growth to $5,631M and Adjusted EBITDA of $1,355M (+23.3%, 24.1% margin), but $97M of the revenue and a $147M favorable net impact on Adjusted EBITDA came from the Conifer/CommonSpirit transition catch-up, not core operations; net income available to common was $1.000 billion ($12.41 diluted) versus $342M ($3.86), with adjusted diluted EPS of $6.64 versus $3.70. Volumes grew modestly (same-hospital admissions +2.8%, adjusted admissions +3.2%) while payer mix worsened — charity and uninsured admissions +26.0% and lower exchange admissions — and labor cost fell (salaries, wages and benefits 38.6% of revenue versus 41.7%). Cash was $2.674 billion at September 30, 2026, $255M went to buybacks in the quarter, and FY 2026 Adjusted EBITDA guidance was raised to $5.05–$5.20 billion. Risk factors were unchanged from the FY2025 10-K.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.